Dr. Steven Nissen shares his take
An expert’s take on four trials in three minutes
Also finds PCSK9 inhibitor more potent than ezetimibe in statin-intolerant patients
Evolocumab halves cardiovascular events in exploratory analysis
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
New agents show powerful cholesterol-lowering ability—and appear safe so far